Although, in the STEP trials, there was a small difference in the 6MWT traversed between those with T2D and those without, we chose not to stratify by the presence of diabetes at baseline because the use of SGLT2-i might be a more relevant factor in influencing outcomes in individuals with HFpEF. Here, SLC5A2 is linked to type 2 diabetes mellitus.